Healthcare Professionals
Start Form

Contact Us

Acthar Logo
Home > Contact Us

To report a side effect/adverse drug experience or quality complaint, please call Mallinckrodt at 1-800-778-7898.

If you have a non-emergency, product-related question, please call Mallinckrodt at 1-800-778-7898 or e-mail us at medinfo@mallinckrodt.com.

For questions regarding insurance or reimbursement coverage for Acthar, please call the Acthar Support & Access Program at 1-888-435-2284.

Acthar Indication Statements

Acthar® Gel (repository corticotropin injection) is used for:

  • Treatment for flares or on a regular basis (maintenance) in people with systemic lupus erythematosus (lupus)
  • Treatment of infantile spasms in infants and children under 2 years of age
  • Treatment for adults with acute relapses or flares of multiple sclerosis (MS). Studies have shown Acthar Gel to be effective in speeding recovery from an MS relapse. However, there is no evidence that Acthar affects the ultimate outcome or natural history of the disease
  • The reduction of proteinuria in people with nephrotic syndrome of the idiopathic type (unknown origin) without uremia (accumulation of urea in the blood due to malfunctioning kidneys) or that due to lupus erythematosus (lupus)
  • Treatment for flares or on a regular basis (maintenance) in people with systemic dermatomyositis or polymyositis (DM-PM)
  • Treatment for people experiencing symptoms of sarcoidosis
  • Adjunctive therapy for short-term administration (to tide patients over an acute episode or exacerbation) in: psoriatic arthritis (PsA); rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis
  • Treatment of severe acute and chronic allergic and inflammatory conditions affecting different parts of the eye. This can include the front part of the eye such as the cornea and iris, or the back part of the eye such as the optic nerve and retina

Acthar Indication Statements

Acthar® Gel (repository corticotropin injection) is indicated for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
  • The treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
  • Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis
  • Treatment of severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation

Terms and Conditions:

  • The Acthar Commercial Co-pay Program provides drug co-pay assistance of up to $25,000 per calendar year for eligible patients
  • This program is valid for eligible, privately and commercially insured patients. For more details about the eligibility criteria, see below
  • This program is not valid for prescriptions for which payment may be made in whole or in part under federal or state health programs, including but not limited to Medicare or Medicaid
  • This program is not valid for uninsured patients
  • Program offer is limited to one membership per person and is not transferrable
  • Patients should consult their insurance provider concerning any limitations that may apply to this program under their insurance policy
  • The program does not represent prescription drug coverage or insurance and is not intended to substitute for such coverage
  • Patients are responsible for any co-payment or coinsurance costs above and beyond the program’s annual maximum benefit
  • Void where prohibited by law
  • Not valid outside the United States
  • Mallinckrodt ARD, Inc. reserves the right to terminate or modify this program at any time without notice

Eligibility Criteria:

  • Approved indication
  • US permanent resident
  • Patient (or patient’s legal representative) must be 18 years of age or older to opt in to program
  • Commercially or privately insured
  • Not insured by a federal or state healthcare plan or where prohibited by law

SEE More SEE More

IMPORTANT SAFETY INFORMATION

DO NOT take Acthar until you have talked to your doctor if you have any of the following conditions:

  • A skin condition called scleroderma
  • Bone density loss or osteoporosis
  • Any infections, including fungal, bacterial, or viral
  • Eye problems, such as ocular herpes simplex

What is Acthar Gel?

Acthar® Gel (repository corticotropin injection) is used for:

  • Treatment for flares or on a regular basis (maintenance) in people with systemic lupus erythematosus (lupus)
  • Treatment of infantile spasms in infants and children under 2 years of age
  • Treatment for adults with acute relapses or flares of multiple sclerosis (MS). Studies have shown Acthar Gel to be effective in speeding recovery from an MS relapse. However, there is no evidence that Acthar affects the ultimate outcome or natural history of the disease